News & Updates

Video call–based peer support intervention significantly increases the rate of exclusive breastfeeding at 2 months postpartum and improves maternal breastfeeding self-efficacy, researchers from the University of Hong Kong (HKU) have found.

Children born to mothers with attention deficit/hyperactivity disorder (ADHD) who used associated medications during pregnancy do not seem to have adverse early childhood development, according to a retrospective study from the Netherlands.

Combining high-dose vitamin D supplementation (VDS) with enuresis alarm (EA) therapy results in significant reductions in wet-night frequency and improves treatment response, satisfaction, and quality of life (QoL) relative to EA alone in children with primary monosymptomatic nocturnal enuresis (PMNE) and serum 25-hydroxyvitamin D (25[OH]D) levels below 30 ng/mL, a study has shown.

Children and adolescents who present to the emergency department (ED) for self-harm are at increased risk of subsequent visit to health services for sexual abuse or assault, a study has found.

In paediatric patients with appendicitis, the use of cefuroxime/metronidazole appears adequate for uncomplicated cases, while treatment with piperacilline/tazobactam may perform better for complicated cases, according to a study.

Daily skin cleansing with octenidine wipes holds no advantage over sterile water in reducing the incidence of late-onset sepsis in neonates admitted to the neonatal intensive care unit (NICU), according to a study.

Abdominal massage combined with standard laxative therapy significantly reduces constipation severity and faecal incontinence in children with functional constipation, according to a study presented at ESPGHAN 2026.

No significant association exists between antibody positivity and household size, household member history of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) illness, activities, or masking, according to a study involving COVID-19-unvaccinated children.

New drug applications approved by US FDA as of 1-15 July 2026 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.